Tag: microport

ECLS Company Hemovent has been Acquired by MicroPort and Receives Investments in Expansion of German Operations

AACHEN, Germany & SHANGHAI–(BUSINESS WIRE)–MicroPort Scientific Corporation (hereinafter referred to as “MicroPort®”) announced on October 4th, 2021, through its critical care subsidiary, MicroPort Surgical B.V. (“MicroPort® Surgery”), has acquired 100% of the equity held by existing shareholders of Hemovent GmbH (hereinafter referred […]

MicroPort® Cardiac Rhythm Management Business Announces US$150 Million Series C Investment

SHANGHAI, July 27, 2021 /PRNewswire/ — MicroPort Scientific Corporation (“MicroPort®“) announced that MicroPort Cardiac Rhythm Management Limited (“MicroPort® CRM“), which is MicroPort®‘s subsidiary focused on developing and commercializing implantable pacemaker and defibrillator devices and related technologies to manage cardiac rhythm disorders, has entered […]

Robocath finalizes creation of the joint venture with MicroPort through its medical robotic subsidiary MedBot

Rouen, France, November 2, 2020 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces creation of the joint venture with MicroPort Scientific Corporation ‘MicroPort’, through ‘MedBot’, its MicroPort MedBot […]

Rapid Medical Raises $20 Million in New Funding to Support Clinical and Commercialization of First-in-class Stroke Treatment Products

YOKNEAM, Israel, April 23, 2019 /PRNewswire/ — Rapid Medical, a company focused on the development of interventional neurovascular devices, announced today that it has completed an oversubscribed Series C financing of $20 million. The proceeds will be used for the completion of the […]

Firehawk® Clinical Data From The TARGET AC European Clinical Trial Has Been Accepted For Publication In The Prestigious Medical Journal The Lancet

SHANGHAI, Sept. 3, 2018 /PRNewswire/ — MicroPort Scientific Corporation (“MicroPort®”, HK:0853) announced today that the clinical trial results for its Firehawk® Rapamycin Target Eluting Coronary Stent System (“Firehawk®”) which conducted a multi-center, randomized controlled trial called TARGET AC has been published online in […]

LivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 Million

LONDON & SHANGHAI–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) and MicroPort Scientific Corporation (HK:00853) (“MicroPort”) today announced that the companies have entered into a binding Letter of Intent (“LOI”) for the sale of LivaNova’s Cardiac Rhythm Management (“CRM”) Business Franchise to MicroPort […]